Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia
• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both...
Ausführliche Beschreibung
Autor*in: |
Vetro, Calogero [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020transfer abstract |
---|
Umfang: |
8 |
---|
Übergeordnetes Werk: |
Enthalten in: 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study - Mohty, Dania ELSEVIER, 2016, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:240 ; year:2020 ; pages:15-22 ; extent:8 |
Links: |
---|
DOI / URN: |
10.1016/j.cancergen.2019.10.006 |
---|
Katalog-ID: |
ELV04876048X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV04876048X | ||
003 | DE-627 | ||
005 | 20230626022730.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200108s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cancergen.2019.10.006 |2 doi | |
028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica |
035 | |a (DE-627)ELV04876048X | ||
035 | |a (ELSEVIER)S2210-7762(19)30470-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
082 | 0 | 4 | |a 380 |q VZ |
084 | |a 55.82 |2 bkl | ||
100 | 1 | |a Vetro, Calogero |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia |
264 | 1 | |c 2020transfer abstract | |
300 | |a 8 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. | ||
520 | |a • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. | ||
700 | 1 | |a Haferlach, Torsten |4 oth | |
700 | 1 | |a Meggendorfer, Manja |4 oth | |
700 | 1 | |a Stengel, Anna |4 oth | |
700 | 1 | |a Jeromin, Sabine |4 oth | |
700 | 1 | |a Kern, Wolfgang |4 oth | |
700 | 1 | |a Haferlach, Claudia |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Mohty, Dania ELSEVIER |t 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019379730 |
773 | 1 | 8 | |g volume:240 |g year:2020 |g pages:15-22 |g extent:8 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.cancergen.2019.10.006 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
936 | b | k | |a 55.82 |j Güterverkehr |q VZ |
951 | |a AR | ||
952 | |d 240 |j 2020 |h 15-22 |g 8 |
author_variant |
c v cv |
---|---|
matchkey_str |
vetrocalogerohaferlachtorstenmeggendorfe:2020----:yoeeiadoeuagntchrceiainfm2pdoiiectmeodekmanoprsno |
hierarchy_sort_str |
2020transfer abstract |
bklnumber |
55.82 |
publishDate |
2020 |
allfields |
10.1016/j.cancergen.2019.10.006 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica (DE-627)ELV04876048X (ELSEVIER)S2210-7762(19)30470-3 DE-627 ger DE-627 rakwb eng 610 VZ 380 VZ 55.82 bkl Vetro, Calogero verfasserin aut Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. Haferlach, Torsten oth Meggendorfer, Manja oth Stengel, Anna oth Jeromin, Sabine oth Kern, Wolfgang oth Haferlach, Claudia oth Enthalten in Elsevier Science Mohty, Dania ELSEVIER 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study 2016 Amsterdam [u.a.] (DE-627)ELV019379730 volume:240 year:2020 pages:15-22 extent:8 https://doi.org/10.1016/j.cancergen.2019.10.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 240 2020 15-22 8 |
spelling |
10.1016/j.cancergen.2019.10.006 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica (DE-627)ELV04876048X (ELSEVIER)S2210-7762(19)30470-3 DE-627 ger DE-627 rakwb eng 610 VZ 380 VZ 55.82 bkl Vetro, Calogero verfasserin aut Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. Haferlach, Torsten oth Meggendorfer, Manja oth Stengel, Anna oth Jeromin, Sabine oth Kern, Wolfgang oth Haferlach, Claudia oth Enthalten in Elsevier Science Mohty, Dania ELSEVIER 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study 2016 Amsterdam [u.a.] (DE-627)ELV019379730 volume:240 year:2020 pages:15-22 extent:8 https://doi.org/10.1016/j.cancergen.2019.10.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 240 2020 15-22 8 |
allfields_unstemmed |
10.1016/j.cancergen.2019.10.006 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica (DE-627)ELV04876048X (ELSEVIER)S2210-7762(19)30470-3 DE-627 ger DE-627 rakwb eng 610 VZ 380 VZ 55.82 bkl Vetro, Calogero verfasserin aut Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. Haferlach, Torsten oth Meggendorfer, Manja oth Stengel, Anna oth Jeromin, Sabine oth Kern, Wolfgang oth Haferlach, Claudia oth Enthalten in Elsevier Science Mohty, Dania ELSEVIER 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study 2016 Amsterdam [u.a.] (DE-627)ELV019379730 volume:240 year:2020 pages:15-22 extent:8 https://doi.org/10.1016/j.cancergen.2019.10.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 240 2020 15-22 8 |
allfieldsGer |
10.1016/j.cancergen.2019.10.006 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica (DE-627)ELV04876048X (ELSEVIER)S2210-7762(19)30470-3 DE-627 ger DE-627 rakwb eng 610 VZ 380 VZ 55.82 bkl Vetro, Calogero verfasserin aut Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. Haferlach, Torsten oth Meggendorfer, Manja oth Stengel, Anna oth Jeromin, Sabine oth Kern, Wolfgang oth Haferlach, Claudia oth Enthalten in Elsevier Science Mohty, Dania ELSEVIER 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study 2016 Amsterdam [u.a.] (DE-627)ELV019379730 volume:240 year:2020 pages:15-22 extent:8 https://doi.org/10.1016/j.cancergen.2019.10.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 240 2020 15-22 8 |
allfieldsSound |
10.1016/j.cancergen.2019.10.006 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica (DE-627)ELV04876048X (ELSEVIER)S2210-7762(19)30470-3 DE-627 ger DE-627 rakwb eng 610 VZ 380 VZ 55.82 bkl Vetro, Calogero verfasserin aut Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. • To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. Haferlach, Torsten oth Meggendorfer, Manja oth Stengel, Anna oth Jeromin, Sabine oth Kern, Wolfgang oth Haferlach, Claudia oth Enthalten in Elsevier Science Mohty, Dania ELSEVIER 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study 2016 Amsterdam [u.a.] (DE-627)ELV019379730 volume:240 year:2020 pages:15-22 extent:8 https://doi.org/10.1016/j.cancergen.2019.10.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 55.82 Güterverkehr VZ AR 240 2020 15-22 8 |
language |
English |
source |
Enthalten in 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study Amsterdam [u.a.] volume:240 year:2020 pages:15-22 extent:8 |
sourceStr |
Enthalten in 0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study Amsterdam [u.a.] volume:240 year:2020 pages:15-22 extent:8 |
format_phy_str_mv |
Article |
bklname |
Güterverkehr |
institution |
findex.gbv.de |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study |
authorswithroles_txt_mv |
Vetro, Calogero @@aut@@ Haferlach, Torsten @@oth@@ Meggendorfer, Manja @@oth@@ Stengel, Anna @@oth@@ Jeromin, Sabine @@oth@@ Kern, Wolfgang @@oth@@ Haferlach, Claudia @@oth@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
ELV019379730 |
dewey-sort |
3610 |
id |
ELV04876048X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV04876048X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626022730.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200108s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cancergen.2019.10.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV04876048X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S2210-7762(19)30470-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">380</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">55.82</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vetro, Calogero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Torsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meggendorfer, Manja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stengel, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jeromin, Sabine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kern, Wolfgang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Claudia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Mohty, Dania ELSEVIER</subfield><subfield code="t">0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019379730</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:240</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:15-22</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cancergen.2019.10.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">55.82</subfield><subfield code="j">Güterverkehr</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">240</subfield><subfield code="j">2020</subfield><subfield code="h">15-22</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
author |
Vetro, Calogero |
spellingShingle |
Vetro, Calogero ddc 610 ddc 380 bkl 55.82 Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia |
authorStr |
Vetro, Calogero |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019379730 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health 380 - Commerce, communications & transportation |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 VZ 380 VZ 55.82 bkl Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia |
topic |
ddc 610 ddc 380 bkl 55.82 |
topic_unstemmed |
ddc 610 ddc 380 bkl 55.82 |
topic_browse |
ddc 610 ddc 380 bkl 55.82 |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
t h th m m mm a s as s j sj w k wk c h ch |
hierarchy_parent_title |
0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study |
hierarchy_parent_id |
ELV019379730 |
dewey-tens |
610 - Medicine & health 380 - Commerce, communications & transportation |
hierarchy_top_title |
0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV019379730 |
title |
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia |
ctrlnum |
(DE-627)ELV04876048X (ELSEVIER)S2210-7762(19)30470-3 |
title_full |
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia |
author_sort |
Vetro, Calogero |
journal |
0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study |
journalStr |
0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology 300 - Social sciences |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
zzz |
container_start_page |
15 |
author_browse |
Vetro, Calogero |
container_volume |
240 |
physical |
8 |
class |
610 VZ 380 VZ 55.82 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Vetro, Calogero |
doi_str_mv |
10.1016/j.cancergen.2019.10.006 |
dewey-full |
610 380 |
title_sort |
cytogenetic and molecular genetic characterization of kmt2a-ptd positive acute myeloid leukemia in comparison to kmt2a-rearranged acute myeloid leukemia |
title_auth |
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia |
abstract |
• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. |
abstractGer |
• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. |
abstract_unstemmed |
• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
title_short |
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia |
url |
https://doi.org/10.1016/j.cancergen.2019.10.006 |
remote_bool |
true |
author2 |
Haferlach, Torsten Meggendorfer, Manja Stengel, Anna Jeromin, Sabine Kern, Wolfgang Haferlach, Claudia |
author2Str |
Haferlach, Torsten Meggendorfer, Manja Stengel, Anna Jeromin, Sabine Kern, Wolfgang Haferlach, Claudia |
ppnlink |
ELV019379730 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth |
doi_str |
10.1016/j.cancergen.2019.10.006 |
up_date |
2024-07-06T19:43:26.498Z |
_version_ |
1803860056735744000 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV04876048X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626022730.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200108s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cancergen.2019.10.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000836.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV04876048X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S2210-7762(19)30470-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">380</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">55.82</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vetro, Calogero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• To define the biological differences in acute myeloid leukaemia (AML) with KMT2A gene involvement and their prognostic impact, we compared 190 de novo AML patients at diagnosis, 95 harbouring KMT2A-rearrangement (KMT2Ar) and 95 KMT2A-PTD, performing cytogenetic and molecular genetic analyses. Both AML subtypes had an unfavourable outcome, particularly in patients older than 60. Patients with KMT2Ar were younger compared to patients with KMT2A-PTD (mean 52 vs 65 years, p < 0.001) and had a higher rate of additional cytogenetic abnormalities (ACA) (46% vs 25% of cases). • In both groups, occurrence of ACA did not influence the overall survival (OS). Regarding molecular genetics, 66% of patients with KMT2Ar and 99% of patients with KMT2A-PTD had additional gene mutations. In multivariate analysis, KRAS mutations and 10p12 rearrangement resulted as adverse prognostic factors in KMT2Ar subgroup. In the KMT2A-PTD group, apart from age, only the occurrence of DNMT3A non-R882 mutations correlated with shorter OS.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Torsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meggendorfer, Manja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stengel, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jeromin, Sabine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kern, Wolfgang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haferlach, Claudia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Mohty, Dania ELSEVIER</subfield><subfield code="t">0488: Assessment of aortic regurgitation severity: a cardiac magnetic resonance and echocardiographic comparison study</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019379730</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:240</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:15-22</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.cancergen.2019.10.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">55.82</subfield><subfield code="j">Güterverkehr</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">240</subfield><subfield code="j">2020</subfield><subfield code="h">15-22</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
score |
7.4011145 |